相关实验视频

Updated: Jun 29, 2025

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

在乳房保护手术后,在下淋巴结解剖后减少血清瘤形成的血液阻塞血静剂

Mohamed Izzad Isahak¹, Muhammad Safwan Abdullah¹, Raflis Ruzairee Awang²

¹Department of Surgery, Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia.

World journal of surgery

|April 5, 2024

概括

血栓阻塞血液静止溶液没有减少血清瘤并发症,也没有改善乳腺癌下淋巴结解剖 (ALND) 后的排水时间. 需要进一步的研究,以了解ALND后的血清瘤形成.

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
乳腺癌管理乳腺癌管理

背景情况:

骨淋巴结解剖 (ALND) 是乳腺癌治疗中的一个关键程序.
血清瘤形成是ALND后的常见并发症,可能会延迟治疗.
研究减轻ALND后并发症的方法对于患者的康复至关重要.

研究的目的:

评估Haemoblock静血溶液在ALND后减少血清瘤并发症方面的疗效.
评估Haemoblock对淋巴流和股死空间消灭的影响.
为了确定Haemoblock是否影响排水清除时间和手术部位感染 (SSI) 率.

主要方法:

一项前性,随机,双盲受控试验,涉及58名接受乳腺保护手术 (BCS) 和ALND.的患者.
患者被分为两个组:ALND + 血液阻塞 (n=29) 和ALND + 安慰剂 (n=29).
主要终点:清除排水的时间. 二级终点:总排水输出,血清吸收率和SSI率.

主要成果:

在Haemoblock组 (398 ± 205毫升) 和安慰剂组 (326 ± 198毫升) 之间的平均总排水量没有统计学上显著的差异 (p=0.176).
在两组中,排水去除的平均时间相似 (6±3.0天) (p=0.526).
在Haemoblock组的9名患者和安慰剂组的6名患者中,需要进行血清吸血 (p=0.222),SSI率没有显著差异.

结论:

血栓阻塞血静液在ALND后减少血清细胞生成方面没有显著的影响.
该溶液没有加快排水的清除,也没有影响手术部位感染率.
血清瘤形成是复杂的,这表明需要对联合干预和延长后续进行进一步研究.

关键词:

乳房乳房乳房乳房教育教育教育教育的教育.瘤学在瘤学方面.结果就是结果.

更多相关视频

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

相关概念视频

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia

Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia

Intravenous regional anesthesia or the Bier block technique is used to anesthetize a specific limb or extremity. It uses exsanguinated or blood-drained vessels to transport local anesthetics or LAs to the peripheral nerve trunks. Lidocaine without vasoconstrictors like epinephrine is most commonly used for this technique. Other drugs used are prilocaine, ropivacaine, and chloroprocaine. Bupivacaine is not recommended for this technique due to its high cardiac toxicity.
One of the advantages of...